PolyPeptide Group AG
Research PolyPeptide Group AG (PPGN) on Bullrun: market cap CHF 1.31B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPPGN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCHF
- Market capCHF 1.31B
- Financial periodFY2025
- RevenueCHF 391.87M
- Revenue growth15.7%
- Net income-CHF 21.17M
- Free cash flow-CHF 31.40M
- Gross margin17.0%
Valuation Snapshot
latest market cap is CHF 1.31B.
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services.
Frequently asked questions
What is PolyPeptide Group AG's market cap?
PolyPeptide Group AG's market capitalization is CHF 1.31B.
What does PolyPeptide Group AG do?
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products.